Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 11/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 4/20 | 0.41 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20187460 | 0.79 | SMN1; SMN2 (0.45) | TRPA1TSHR | |
| SCHEMBL20203176 | 0.78 | TRPA1 (0.41) | TRPA1HPGD | |
| SCHEMBL20187457 | 0.78 | KDM4E (0.48) | TRPA1PKM | |
| SCHEMBL13804449 | 0.77 | TRPA1 (0.51) | TRPA1PKMGSK3AGSK3BCDK1 | |
| SCHEMBL21363364 | 0.75 | TRPA1 (0.50) | TRPA1PKMGSK3AGSK3BCDK1 | |
| SCHEMBL20187600 | 0.75 | TRPA1 (0.52) | TRPA1 | |
| SCHEMBL22477750 | 0.74 | GSK3A (0.39) | TRPA1GSK3AGSK3BCDK1CCNB1 | |
| SCHEMBL21363471 | 0.74 | TRPA1 (0.37) | TRPA1 | |
| SCHEMBL20203244 | 0.74 | TRPA1 (0.39) | TRPA1GSK3AGSK3BCDK1CCNB1 | |
| SCHEMBL20203315 | 0.74 | TRPA1 (0.45) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | TRPA1 1/4885PKM 3241/4885GSK3A 1508/4885 |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | TRPA1 1/4885PKM 3241/4885GSK3A 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.